The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.50
Bid: 0.40
Ask: 0.60
Change: 0.00 (0.00%)
Spread: 0.20 (50.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.50
SUN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Distalmotion’s Dexter Robot receives CE Mark

8 Jan 2021 07:00

RNS Number : 9916K
Surgical Innovations Group PLC
08 January 2021
 

Surgical Innovations Group plc("Surgical Innovations", "SI" or the "Company")

 

Distalmotion's Dexter Robot receives CE Mark

 

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces that Distalmotion SA, a Swiss-based medical device company providing robotic surgery systems on a transparent and fair per-procedure cost ("Distalmotion"), has received European CE Mark for its 'Dexter' surgical robot. Manufactured in Switzerland, Dexter combines the affordability of laparoscopy with the benefits of robotic surgery to bring simplicity and versatility in minimally invasive surgical care. 

 

Elemental Healthcare Limited, a wholly owned SI subsidiary, has exclusive UK distribution rights for the Dexter Robot.

 

The European CE mark remains valid in the UK post Brexit.

 

Adam Power, SI Group Development Director, commented: "The UK minimally invasive surgical robot market has been dominated by a single, expensive and very complex robot for nearly two decades. Dexter is designed to integrate readily into existing laparoscopic procedures and its simplicity and versatility makes robotics accessible for a wider range of procedures. The regulatory approval of the Dexter operating robot now allows the introduction of a disruptive robotic model to UK healthcare. The ease of use, affordability and Swiss manufacturing excellence will be significant factors in the growth opportunity for this new robot."

 

Michael Friedrich, CEO, Distalmotion said: "Distalmotion are looking forward to some early successes in the important UK market with our partner, Elemental Healthcare. The NHS is especially appropriate for the Dexter strategic model of selling and we already have hospitals that are some way into the process of product acquisition."

 

 

For further information please contact:

 

Surgical Innovations Group plc

www sigroupplc com

David Marsh, CEO

Tel: 0113 230 7597

Charmaine Day, Co Sec & GFC

 

 

 

N+1 Singer (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell (Corporate Finance)

 

Rachel Hayes (Corporate Broking)

 

 

 

Walbrook PR (Financial PR & Investor Relations)

Tel: 020 7933 8780 or si@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part re-usable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

In addition, we design and develop medical devices for carefully selected OEM partners, and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

 

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.

 

The Group currently employs approximately 100 people across two sites in the UK. Product design, engineering and manufacturing are carried out at the SI site in Yorkshire. Commercial activities including marketing, UK distribution and international sales and marketing are based at Elemental Healthcare in Berkshire.

 

Further information

Further details of the Group's businesses are available on the following websites:

www.sigroupplc.com

www.surginno.com 

www.elementalhealthcare.co.uk

To receive regular updates by email, please contact si@walbrookpr.com.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFLDLDIDIIL
Date   Source Headline
18th Oct 20137:00 amRNSCFO to present at London Investor Show
17th Oct 20137:00 amRNSInternational Clinical Advisory Board Appointment
4th Oct 20137:00 amRNSAppointment to the Clinical Advisory Board
10th Sep 20137:00 amRNSInterim Results
16th Aug 20137:00 amRNSTrading update
19th Jun 20134:06 pmRNSResult of AGM
19th Jun 20132:00 pmRNSAGM Statement
10th Jun 20137:00 amRNSPilot hip arthroscopy test
3rd Jun 20137:00 amRNSAppointment to the Clinical Advisory Board
29th May 20137:00 amRNSNew US dealer
22nd May 20137:00 amRNSDevelopment agreement for Industrial application
8th May 20137:00 amRNSSnr Appointment of President US Sales & Operations
17th Apr 20137:00 amRNSAppointment to the Clinical Advisory Board
9th Apr 20137:00 amRNSPreliminary Results
18th Mar 20137:00 amRNSChange of Adviser
11th Mar 20137:00 amRNSUS appointment to ICAB
19th Feb 20137:00 amRNSTrading Update
23rd Jan 20137:00 amRNSPretzelFlex 3mm FDA approval
22nd Jan 20137:00 amRNSSecond order of 5mm PretzelFlex® shipped
17th Jan 20137:00 amRNSSI to benefit from £5.05m RGF Grant
10th Jan 20137:00 amRNSDirectors shareholding
18th Dec 20129:24 amRNSDirectors' dealings and issue of equity
18th Dec 20127:00 amRNSAppointments to the Clinical Advisory Board
29th Oct 20127:00 amRNSFirst PretzelFlex® orders shipped to CareFusion
11th Oct 20127:00 amRNSSuccessful exhibition at ISHA in the US
18th Sep 20127:00 amRNSHalf Yearly Report
4th Sep 20127:00 amRNSNotice of Results
30th Aug 20122:14 pmRNSHolding(s) in Company
26th Jun 20127:00 amRNSGrant of options
19th Jun 20123:33 pmRNSResult of AGM
19th Jun 20127:00 amRNSAGM Statement
18th Jun 20127:00 amRNSOEM distribution agreement with CareFusion
31st May 20127:00 amRNSUK distribution agreement
25th May 201211:58 amRNSDirectorate Change
22nd May 20127:00 amRNSPublication of Annual Report and Notice of AGM
1st May 20127:00 amRNSInvestor site visit
24th Apr 20127:00 amRNSFinal Results
20th Apr 20127:00 amRNSNotice of Results
15th Mar 20127:00 amRNSFDA 510(k) approval for reusable PretzelFlexT
23rd Feb 20124:54 pmRNSHolding(s) in Company
17th Feb 20124:36 pmRNSDirector/PDMR Shareholding
14th Feb 20125:49 pmRNSIssue of Equity
1st Feb 20127:00 amRNSRe: US contract and FDA approval
23rd Jan 20127:01 amRNSTrading Statement
2nd Dec 20117:00 amRNSInvestor Site Visit
3rd Nov 20117:00 amRNSIssue of Equity
1st Nov 20117:00 amRNSConfirmation of successful RGF bid
21st Sep 20114:49 pmRNSIssue of Equity
14th Sep 20117:00 amRNSHalf Yearly Report
1st Sep 20115:23 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.